Breakthrough Bleeding with Combined Hormonal Contraception

alicia59792 diane50772 rebecca36797 678 Users are discussing this topic

PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.

See also: Migraine and the Contraceptive Pill or the Contraceptive Patch written for patients

Most women find that combined hormonal contraception (CHC) provides reliable cycle control.

Indeed the combined oral contraceptive pill (COCP) is often prescribed for the management of menstrual disorders such as menorrhagia and dysfunctional uterine bleeding.[1][2] 

However, although new formulations with low doses of oestrogen offer health benefits, they may provide less satisfactory cycle control.[3] The risk of bleeding may also be related to the dose and type of progestogen. It may be that third-generation COCPs are associated with less menstrual irregularity. Unfortunately, methodological differences between studies have also made it difficult to compare rates of breakthrough bleeding between different preparations.[4] 

Irregular bleeding whilst taking CHC is a common problem. Up to 20% of women experience breakthrough bleeding or spotting.[5] Bleeding usually settles with time, and it is therefore recommended that women persevere for three months before considering changing their contraceptive pill.[6] 

NEW - log your activity

  • Notes
    Add notes to any clinical page and create a reflective diary
  • Track
    Automatically track and log every page you have viewed
  • Print
    Print and export a summary to use in your appraisal
Click to find out more »

Normal endometrial maturation depends on complex interactions between oestrogen and progesterone. CHC provides a continuous supply of oestrogen and progestogen to the endometrium. The low dose of oestrogen in modern CHCs is insufficient to maintain endometrial integrity and the opposing effect of progestogen promotes atrophy of glands and stroma. The resulting endometrium is thin, fragile and prone to bleeding. The exact mechanisms of bleeding associated with CHC are not well understood, but the frailty of blood vessels within the endometrium appears to be a factor, along with changes in local endometrial concentrations of, and response to, hormones.[5][7] 

No relationship has been identified between serum steroid levels, unscheduled bleeding and loss of efficacy.[6] In the absence of missed or late pills, vomiting or drug interactions, lack of contraceptive efficacy has not been proven.

Patient factors[5] 

  • Adherence. Missed pills are the most likely cause of irregular bleeding.
  • Cigarette smoking has anti-oestrogenic properties and may affect cycle control.
  • Medication interaction. Certain prescribed medications, as well as over-the-counter preparations such as St John's wort can interfere with hormonal levels.
  • Non-CHC-related causes of bleeding, which must be considered. (See 'Other considerations', below.)

CHC formulation factors

  • COCPs containing only 20 micrograms of ethinylestradiol (EE) cause more disrupted bleeding patterns than those containing higher doses.[3] 
  • There is no evidence yet that biphasic, triphasic or quadriphasic preparations confer better control than standard monophasic preparations.[8][9][10] 
  • First-generation progestogens (eg, norethisterone) may provide poorer cycle control than second-generation (levonorgestrel) and third-generation progestogens. However, a Cochrane review determined that trial methodology is flawed and this has not yet been proven.[4] 
  • There is no significant difference between CHC pills and CHC patches in terms of irregular bleeding.[7] 
  • Incidence of breakthrough bleeding with the vaginal ring is lower than with the COCP.[5] 
  • Women using extended cycle regimes to control timing of menses may experience more breakthrough bleeding. (This can be improved by tailoring their pill use. Advise them to continue taking the pill until breakthrough bleeding occurs, then to have a break, and thereafter to use this as a guide for when to have a break.)[5] 


Take a clinical history to assess:

  • The woman's concerns.
  • Correct use of the method (eg, pill taking, patch use),
  • Use of interacting medication - including over-the-counter remedies.
  • Illness altering absorption of orally administered hormones.
  • Other symptoms (eg, pain, dyspareunia, abnormal vaginal discharge, heavy bleeding, postcoital bleeding).
  • History of, risks for, sexually transmitted infections.
  • Cervical screening history.
  • The need to consider a pregnancy test.


Speculum examination is indicated where there is consistent correct use of the CHC method for more than three months with persistent irregular bleeding and/or:[11] 

  • Pain.
  • Dyspareunia.
  • Vaginal discharge.
  • Postcoital bleeding.
  • No history of regular cervical smears.
  • Ongoing symptoms despite change to a different CHC or other contraceptive method after 6-8 weeks.
  • New onset of bleeding after three months.
  • Request for examination by the woman.

If there are symptoms suggestive of sexually transmitted infections, swabs should be taken or a referral made to the local genitourinary medicine (GUM) clinic. Risk factors include age under 25 years, a new sexual partner, and having had more than one sexual partner in the preceding year.

Other considerations[5][11] 

Although CHC is a common cause of irregular bleeding, other unrelated causes must also be considered such as:

Evidence is not yet of sufficient quality for there to be evidence-based guidelines or recommendations. Having excluded other causes:

  • Reassure patients that breakthrough bleeding is a common side-effect of CHC and usually resolves after three cycles of use.
  • Advise women who smoke that stopping smoking may improve cycle control.
  • If bleeding persists after three cycles, consider changing formulation:
    • Increase dose of oestrogen, particularly if on a 20-microgram ethinylestradiol (EE) preparation, to a maximum of 35 micrograms of EE. (There is no evidence that increasing the dose from 30 micrograms to 35 micrograms is effective, but it may work for some women.)
    • Try a preparation with a different progestogen or a higher dose.
    • There is currently no evidence of any particular preparations being better than any others with regard to breakthrough bleeding.
    • Consider the vaginal ring, which has lower rates of breakthrough bleeding.
    • Consider tailored pill use, as above, for women on extended cycle regimes.
  • If bleeding persists despite a different formulation, consider an alternative form of contraception.

Further reading & references

  • Hickey M, Agarwal S; Unscheduled bleeding in combined oral contraceptive users: focus on extended-cycle and continuous-use regimens. J Fam Plann Reprod Health Care. 2009 Oct;35(4):245-8. doi: 10.1783/147118909789587411.
  1. Schindler AE; Non-contraceptive benefits of oral hormonal contraceptives. Int J Endocrinol Metab. 2013 Winter;11(1):41-7. doi: 10.5812/ijem.4158. Epub 2012 Dec 21.
  2. Farquhar C, Brown J; Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev. 2009 Oct 7;(4):CD000154. doi: 10.1002/14651858.CD000154.pub2.
  3. Gallo MF, Nanda K, Grimes DA, et al; 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013 Aug 1;8:CD003989. doi: 10.1002/14651858.CD003989.pub5.
  4. Lawrie TA, Helmerhorst FM, Maitra NK, et al; Types of progestogens in combined oral contraception: effectiveness and side-effects. Cochrane Database Syst Rev. 2011 May 11;(5):CD004861. doi: 10.1002/14651858.CD004861.pub2.
  5. Lumsden MA, Gebbie A, Holland C; Managing unscheduled bleeding in non-pregnant premenopausal women. BMJ. 2013 Jun 4;346:f3251. doi: 10.1136/bmj.f3251.
  6. Combined Hormonal Contraception; Faculty of Sexual and Reproductive Healthcare (2011 updated August 2012)
  7. Management of Unscheduled Bleeding in Women Using Hormonal Contraception; Faculty of Sexual and Reproductive Healthcare (2009)
  8. Van Vliet HA, Grimes DA, Helmerhorst FM, et al; Biphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2006 Jul 19;3:CD002032.
  9. Van Vliet HA, Grimes DA, Lopez LM, et al; Triphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD003553. doi: 10.1002/14651858.CD003553.pub3.
  10. Van Vliet HA, Raps M, Lopez LM, et al; Quadriphasic versus monophasic oral contraceptives for contraception. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD009038. doi: 10.1002/14651858.CD009038.pub2.
  11. Contraception - combined hormonal methods; NICE CKS, June 2012 (UK access only)

Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.

Original Author:
Dr Hayley Willacy
Current Version:
Peer Reviewer:
Prof Cathy Jackson
Document ID:
515 (v10)
Last Checked:
Next Review:

Did you find this health information useful?

Yes No

Thank you for your feedback!

Subcribe to the Patient newsletter for healthcare and news updates.

We would love to hear your feedback!

Patient Access app - find out more Patient facebook page - Like our page